The CBR was 19.2% (95% CI, 6.6–39.4) in all evaluable patients who received 60 mg/day palazestrant (n = 26) and 23.1% (95% CI, 5.0–53.8) among the 13 patients with cancers with ESR1 mutations. Here, ESR1 is linked to cancer.